Skip to main content

$0.076 -0.001 (-1.30%)

High

$0.08

Low

$0.07

Trades

8

Turnover

$9,058

Volume

120,981
30 June 2023 at 2:59pm
Register to track ATX and receive email alerts.

Amplia Completes Dosing in Phase 1 Clinical Study of AMP945

StockBot

416,823 posts

ATX released this announcement to the ASX on 15 April 2021, 8:22. The announcement is marked as price sensitive, and is 1 page(s) in length and 103.52kb in size.

You can view all announcements from ATX and see how they appear on a price chart on the announcements page.

At the date of this announcement, ATX was 0.012% short sold according to ASIC data. It was ranked the 606th most shorted stock on the ASX. It remains ranked 629th as of the latest reported data (26 May 2026).

Other Recent Announcements from ATX
AMP945 International Nonproprietary Name Narmafotinib 21 June 2023, 8:34
Amplia AGM to be held Thursday 24 August 2023 19 June 2023, 17:34
Key to Corporate Governance Disclosures 31 May 2023, 8:14
Amplia Completes Dosing in Phase 1 Clinical Study of AMP945 15 April 2021, 8:22
Amplia Appoints New Non-Executive Director 12 April 2021, 8:48
Change of Registered Office and Principal Place of Business 25 March 2021, 12:03
Appendix 2A - Exercise of Options 24 March 2021, 14:42
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track ATX and receive email alerts.